Diffuse Large-Cell Lymphoma Clinical Trial
Official title:
Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV
Early identification of refractory lymphoma patients provides a basis for stratification between responders to standard approaches and non-responders who may benefit from an early change to an alternative treatment strategy.Metabolic or molecular imaging with fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has emerged as a powerful imaging modality for diagnosis, staging, and therapy monitoring of a variety of cancers. The primary hypothesis of the present study is that early response can be pinpointed by PET reflecting both tumor burden and activity, as a surrogate for final outcome. An increasing number of studies have suggested the potential role of 18F-FDG PET in the staging and monitoring of lymphomas. The optimal timing of PET scans and the potential role of quantitative PET using SUV to assess response to chemotherapy remain to be defined. Confirmation of very early 18F-FDG-PET as a significant predictor of treatment response in a homogenous group of aggressive lymphoma patients would potentially change the prognosis of the patient by allowing earlier use of alternative therapies and discontinuation of therapy that will not lead to a significant tumour response.
Title: Evaluation of response to treatment using 18F-FDG positron emission tomography
imaging (PET) in diffuse large B-cell lymphoma stage IIB-IV with special emphasize on the
prognostic significance of early on-therapy PET at first-line treatment
Study design: Multicenter trial.
Planned sample size: 100 patients.
Number of centers: Denmark 2; Sweden 1; Norway 1; Finland 1.
Aim of the study: 1. To evaluate the prognostic significance of PET early after treatment
initiation. 2. To compare early PET with standard response criteria for NHL and the
International Prognostic Index (IPI) in the prediction of response and outcome.
Primary objective: The prognostic significance of FDG-PET after 1 cycle of chemotherapy.
End-points: Progression-free survival (PFS). Overall survival (OS). Response to treatment
(standardized response criteria) at mid-treatment and post-treatment.
Inclusion criteria:
Age ≥ 18 years. Newly diagnosed consecutive patients with diffuse large B-cell lymphoma
(DLBCL) according to the WHO classification.
Ann Arbor stage IIB-IV. Written informed consent.
Exclusion criteria: Previously treated with chemotherapy or irradiation. Previous malignant
diagnosis except basal cell carcinoma and cervical carcinoma in situ.
Pregnancy. Lactation. Diabetes mellitus. Extreme adipositas. Claustrophobia. Active
inflammatory disease or infection.
PET-CT evaluation: PET and CT at primary staging before initiation of therapy and PET after
one cycle of intravenous chemotherapy (day 10-20) are mandatory. The results of the PET
scans are blinded and will not be available for the local physicians. If the PET result is
opened, the patient will be excluded from the study.
Only post-treatment PET scans are allowed outside the protocol. The local physician may use
post-treatment PET in diagnostic or therapeutic considerations.
Only dedicated full-ring PET scanners are allowed in this study.
Treatment: Therapy with a CHOP-like backbone according to local standards of the individual
centers. Treatment according to other protocols allowed.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01234467 -
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00268853 -
A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
|
Phase 2 | |
| Recruiting |
NCT04745559 -
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
|
Phase 2 | |
| Completed |
NCT00140595 -
ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1
|
Phase 3 |